Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
复制标题
氟他胺作为晚期胰腺癌患者二线化疗的 II 期研究。
DOI：
10.1023/a:1005989519350
复制
发表时间：
1997
影响因子：
3.4
通讯作者：
Rothenberg,ML
中科院分区：
文献类型：
--
作者：
Sharma,JJ;Razvillas,B;Stephens,CD;Hilsenbeck,SG;Sharma,A;Rothenberg,ML
雄激素受体存在于胰腺癌组织和细胞系中。氟替卡松是一种有效的抗雄激素药物，广泛用于转移性前列腺癌患者的临床实践。这项II期试验旨在评价氟替卡松对接受一种以5-FU为基础的方案治疗后发生疾病进展的晚期胰腺癌患者的影响。14例患者接受氟替卡松治疗，250 mg口服，每日3次。治疗通常耐受良好。无患者达到客观肿瘤缓解。通过疼痛强度、镇痛剂需求、体能状态或营养状态的改善测量，无患者的肿瘤相关症状改善。中位生存期为4.7个月。我们的结论是，氟替卡松是无效的二线治疗晚期胰腺癌患者。
Androgen receptors are present in both pancreatic cancer tissue and cell lines. Flutamide is a potent antiandrogen widely used in clinical practice for patients with metastatic prostate cancer. This Phase II trial was undertaken to evaluate the impact of flutamide in patients with advanced pancreatic adenocarcinoma who had developed progressive disease following therapy with one 5-FU-based regimen. Fourteen patients were treated with flutamide, 250 mg orally three times per day. Therapy was generally well tolerated. No patient achieved objective tumor response. No patient had improvement in tumor-related symptoms as measured by improvement in pain intensity, analgesic requirement, performance status, or nutritional status. Median survival was 4.7 months. We conclude that flutamide is ineffective second line therapy for patients with advanced pancreatic adenocarcinoma.